Association between thiopurine smethyltransferase polymorphisms and azathioprine-induced adverse drug reactions in patients with autoimmune diseases: A meta-analysis

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Liu, Yue Ping ^a,b   Xu, Han Qing ^a   Li, Ming ^b   Yang, Xiang ^a   Yu, Shu ^a   Fu, Wei Ling ^a   Huang, Qing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b 477th Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE;

ABDOMINAL PAIN; ADVERSE DRUG REACTION; ARTICLE; ASIAN; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BONE MARROW TOXICITY; CAUCASIAN; DNA POLYMORPHISM; DYSPEPSIA; ETHNIC DIFFERENCE; EUROPEAN; GASTRIC INTOLERANCE; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MEDICAL LITERATURE; META ANALYSIS; NAUSEA; PUBLISHING; SAMPLE SIZE; SENSITIVITY ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TPMT GENE; VOMITING; AUTOIMMUNE DISEASES; GENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

AUTOIMMUNE DISEASES; AZATHIOPRINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84955462663     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144234     Document Type: Article

References (40)

1. Das PK, Elliott G. Conference scene: lessons from animal models of autoimmune diseases: from mechanisms to applications. Immunotherapy. 2011; 3(2):147-151. doi: 10.2217/imt.10.102 PMID: 21322755
2. Sinha AA, Lopez MT, McDevitt HO. Autoimmune diseases: the failure of self tolerance. Science. 1990; 248(4961):1380-1388. PMID: 1972595
3. Goding JW. Autoimmune diseases. N Engl J Med. 2001; 345(23):1707-1708.
4. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43(4):329-339. PMID: 1451710
5. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002; 51(2):143-146. PMID: 12117866
6. Appell ML, Berg J, Duley J, Evans WE, Kennedy MA, Lennard L, et al. Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics. 2013; 23(4):242-248. doi: 10.1097/ FPC.0b013e32835f1cc0 PMID: 23407052
7. Collie-Duguid ES, Pritchard SC, Powrie RH, Sludden J, Collier DA, Li T, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999; 9(1):37-42. PMID: 10208641
8. Engen RM, Marsh S, Van Booven DJ, McLeod HL. Ethnic differences in pharmacogenetically relevant genes. Curr Drug Targets. 2006; 7(12):1641-1648. PMID: 17168839
9. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. American journal of human genetics. 1980; 32(5):651-662. PMID: 7191632
10. Egan LJ, Derijks LJJ, Hommes DW. Pharmacogenomics in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4(1):21-28. PMID: 16431300
11. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther. 2011; 89(3):387-391. doi: 10.1038/clpt.2010.320 PMID: 21270794
12. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther. 2013; 93(4):324-325. doi: 10.1038/clpt.2013.4 PMID: 23422873
13. Anstey AV, Wakelin S, Reynolds NJ, British Association of Dermatologists Therapy G, Audit S. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004; 151(6):1123-1132. PMID: 15606506
14. Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol. 2014; 77(4):704-714. doi: 10.1111/ bcp.12226 PMID: 23962279
15. Booth RA, Ansari MT, Loit E, Tricco AC, Weeks L, Doucette S, et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med. 2011; 154 (12):814-823,W-295-818. doi: 10.7326/0003-4819-154-12-201106210-00009 PMID: 21690596
16. Liu YP, Wu HY, Yang X, Xu HQ, Li YC, Shi DC, et al. Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS One. 2015; 10(3):e0121745. doi: 10.1371/journal.pone.0121745 PMID: 25799415
17. Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. World J Gastroenterol. 2010; 16 (25):3187-3195. PMID: 20593505
18. Gisbert JP, Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol. 2008; 103(7):1783-1800. doi: 10.1111/j.1572-0241.2008.01848.x PMID: 18557712
19. Ishioka S, Hiyama K, Sato H, Yamanishi Y, McLeod HL, Kumagai K, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med. 1999; 38(12):944-947. PMID: 10628931
20. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford). 1999; 38(7):640-644.
21. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol. 2002; 37(4):441-447. PMID: 12217596
22. Corominas H, Domenech M, Laiz A, Gich I, Geli C, Diaz C, et al. Is thiopuriue methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology (Oxford). 2003; 42(1):40-45.
23. Jun JB, Cho DY, Kang C, Bae SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol. 2005; 23(6):873-876. PMID: 16396707
24. Okada Y, Nakamura K, Kodama T, Ueki K, Tsukada Y, Maezawa A, et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus. Biol Pharm Bull. 2005; 28(11):2117-2119. PMID: 16272700
25. Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler DA. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol. 2006; 45(4):584-591. PMID: 16876902
26. Tamori A, Shinzaki M, Kosaka S, Hayashi T, Iwai S, Enomoto M, et al. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver international: official journal of the International Association for the Study of the Liver. 2007; 27(1):95-100.
27. Bezier M, Reguiai Z, Vitry F, Broly F, Bernard P. Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases. Eur J Dermatol. 2008; 18(5):512-517. doi: 10.1684/ejd.2008.0473 PMID: 18693152
28. Tani C, Mosca M, Colucci R, Gori G, D'Ascanio A, Ghisu N, et al. Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases. Clin Exp Rheumatol. 2009; 27(2):321-324. PMID: 19473575
29. Chen D, Lian F, Yuan S, Wang Y, Zhan Z, Ye Y, et al. Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2014; 33(4):499-503. doi: 10.1007/s10067-013-2441-x PMID: 24322830
30. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011; 343:d4002. doi: 10.1136/bmj.d4002 PMID: 21784880
31. de Jong DJ, Derijks LJJ, Naber AHJ, Hooymans PM, Mulder CJJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol. 2003; 38:69-72.
32. Lennard L, Cartwright CS, Wade R, Richards SM, Vora A. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2013; 76(1):125-136. doi: 10.1111/bcp.12066 PMID: 23252716
33. McLeod HL, Pritchard SC, Githang'a J, Indalo A, Ameyaw MM, Powrie RH, et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics. 1999; 9(6):773-776. PMID: 10634140
34. Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther. 1997; 62(1):60-73. PMID: 9246020
35. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE, Van der Woude CJ. Meta-analysis: Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 26(5):643-652. PMID: 17697198
36. Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A, Carpio D, Lorenzo A, Castro J, et al. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving azathioprine. J Gastrointestin Liver Dis. 2011; 20 (3):247-253. PMID: 21961091
37. Zabala W, Cruz R, Barreiro-de Acosta M, Chaparro M, Panes J, Echarri A, et al. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients. Pharmacogenomics. 2013; 14(6):631-640. doi: 10.2217/pgs.13.38 PMID: 23570467
38. Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet. 2014; 46(10):1131-1134. doi: 10.1038/ng.3093 PMID: 25217962
39. Higgs JE, Payne K, Roberts C, Newman WG. Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? Pharmacogenomics. 2010; 11(2):177-188. doi: 10.2217/pgs.09.155 PMID: 20136357
40. Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, et al. Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics. 2010; 20 (6):401-405. doi: 10.1097/FPC.0b013e3283352860 PMID: 20154640